

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 24371

**Title:** HER2 testing in gastric cancer: an update

**Reviewer's code:** 00051382

**Reviewer's country:** China

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2016-01-21 17:08

**Date reviewed:** 2016-01-25 10:23

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[ Y ] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[ Y ] No	

## COMMENTS TO AUTHORS

With the recent introduction of trastuzumab for the treatment of patients with advanced gastric cancer, the clinical demand for HER2 assessment is rapidly increasing. This paper summarized the current evidences regarding HER2 in gastric and gastroesophageal cancer and provided a practical update on HER2 testing and scoring. It will help to screen patients eligible for treatment with trastuzumab. 1. Page 4: "Forty-two publications with a total of 12749 patients were reviewed and the majority (71%) of the publications showed that a HER2-positive status was associated with poor survival and/or clinicopathological characteristics, such as serosal invasion, lymph node metastases, disease stage, or distant metastases." These data should be cited. 2. HER2 TESTING METHODS: Could you give a table to compare the advantages and disadvantages.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 24371

**Title:** HER2 testing in gastric cancer: an update

**Reviewer's code:** 02731948

**Reviewer's country:** Italy

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2016-01-21 17:08

**Date reviewed:** 2016-02-02 00:23

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

An interesting paper.

Monoclonal antibody increased the possibility in gastric cancer treatment.

The manuscript exhaustively review the state of the art of this new therapy option.

In my opinion the manuscript should cite the possibility to use this kind of therapy also intraperitoneally as investigated by some recent studies.